FDA Panel Backs Previously Rejected Obesity Pill
CBS Sacramento (con't)
Affordable Care Act Updates: CBSSacramento.com/ACA
Health News & Information: CBSSacramento.com/Health
Don't Miss This
- Woman Walking With 2-Year-Old Son Hit, Killed By Man Driving Drunk
- Citrus Heights Gaming Hall Actually Slashes Crime In Surrounding Area
- Starting Tuesday, California Law Requires Drivers To Give Cyclists 3 Feet Of Space On Road
- Missing Christian Brothers High School Volleyball Coach Found Alive In Oregon
- Police Detain ‘Django Unchained’ Actress In LA
Get Breaking News First
SILVER SPRING, Md. (AP) — A panel of advisers to the Food and Drug Administration overwhelmingly backed approval for a highly anticipated anti-obesity pill from Vivus Inc., a drug which the FDA previously rejected due to safety concerns.
The FDA panel of outside physicians voted 20-2 in favor of the weight loss drug Qnexa, setting the stage for a potential comeback for a drug that has been plagued by side effects since it was first submitted to the agency in 2010.
A majority of panelists ultimately backed the drug due to its impressive weight loss results, with most patients reporting nearly 10 percent weight loss. But the group stressed the importance of confirming the drug’s safety, particularly its effects the heart, by tracking patients in a large, follow-up study. FDA’s decision is expected in April.
Copyright 2012 The Associated Press.